FDA Brief

Warning letters Drugs

FDA warning letter to

Melcare Biomedical Pty Ltd

High riskIssued Oct 9, 2025Posted Oct 21, 2025Center for Drug Evaluation and Research (CDER)

Australia's Melcare Biomedical sells Optimel Manuka+ eye gel and drops in the US as unapproved drugs with honey as an active ingredient.

What happened

On September 10, 2025, FDA reviewed Melcare's website (melcare.com) and a YouTube video linked from it, and found Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops offered for purchase in the United States without a prescription. The labeling, including the Drug Facts panels, says the products give temporary relief from eye irritation due to dryness and protect against further irritation, and the website says the medical-grade manuka honey helps with moderate to severe dry eye and meibomian gland dysfunction. FDA says honey is not a permitted active ingredient for over-the-counter eye products and that no FDA-approved application is in effect for either product.

What FDA found

  1. The eye gel and drops count as drugs under the law because their labels and website say they relieve dry eye irritation and dryness, and the website says they help with dry eye disease.

    FD&C Act section 201(g)(1)(B) and (C), 21 U.S.C. 321(g)(1)
  2. The products are 'new drugs' being sold without an FDA-approved application, which the law requires.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  3. The products are made with honey, which is not an allowed active ingredient for over-the-counter eye lubricant products under the relevant OTC rule (monograph M018), so they cannot be sold under that rule.

    FD&C Act section 505G, 21 U.S.C. 355h; OTC monograph M018.12
  4. The label calls honey an inactive ingredient, but the website and video present honey as the thing that treats the eye condition, which makes it an active ingredient.

    21 CFR 201.66(b)(2)
  5. Because the products do not meet the OTC requirements and have no approved application, they are misbranded.

    FD&C Act section 502(ee), 21 U.S.C. 352(ee)

What FDA wants

FDA asks the company to write to FDAADVISORY@fda.hhs.gov within 15 working days listing the specific steps taken to correct the violations and prevent them from happening again, with copies of related documents. If the company believes its products are not in violation, it should send its reasoning and supporting information for FDA to consider.

Who should pay attention

  • US retailers and online marketplaces that list imported OTC eye products
  • distributors and brands selling manuka honey eye products with treatment claims
  • companies whose websites and social videos make drug-like claims for OTC products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk